Breast Cancer Clinical Trial
Official title:
Phase I Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) Alone and in Combination With Docetaxel in Subjects With Advanced Solid Malignancies
The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced solid tumors.
2-deoxy-D-glucose (2DG) is a synthetic glucose analog under development by Threshold
Pharmaceuticals, Inc. that exploits the differences in metabolism between normal and
malignant cells. Malignant cells utilize glucose at a much higher rate than normal cells and
are therefore more dependent on aerobic and anaerobic glycolysis. If glycolysis could be
blocked preferentially in malignant cells, 2DG would have potential for anti-tumor therapy.
Hypoxic cells are especially dependent on anaerobic glycolysis and are generally resistant
to anti-tumor therapies such as chemotherapy and radiotherapy. Therefore, combining 2DG with
chemotherapy may be a way to simultaneously target both hypoxic and aerobic cells in tumors.
Four factors may play a role in the preferential toxicity of 2DG in malignant cells: (1)
increased uptake and retention of glucose analogs by malignant cells; (2) relative hypoxia
of tumor cells relative to normal cells; (3) malignant cells may be more sensitive to
glucose deprivation than normal cells; and (4) inhibition of glycolysis may increase
sensitivity to some cytotoxic agents. Preliminary data in human tumor xenografts support
this hypothesis.
Because 2DG is most likely to be effective in combination with chemotherapy, this trial was
designed to evaluate the maximum tolerated dose (MTD) of 2DG both alone and in combination
with chemotherapy. Docetaxel was chosen because there is evidence in human tumor xenografts
of delayed tumor growth for 2DG in combination with paclitaxel compared to paclitaxel alone
and it has been reported that taxanes may enhance uptake of 2DG into malignant cells.
Patients with advanced solid tumors were chosen because they are appropriate candidates for
a Phase I clinical trial and because their tumors are likely to have areas of hypoxia.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |